PT  - JOURNAL ARTICLE
AU  - Chopra, Arvind
AU  - Chavan-Gautam, Preeti
AU  - Tillu, Girish
AU  - Saluja, Manjit
AU  - Borse, Swapnil
AU  - Sarmukaddam, Sanjeev
AU  - Chaudhuri, Susmita
AU  - Rao, BCS
AU  - Yadav, Babita
AU  - Srikanth, Narayanam
AU  - Patwardhan, Bhushan
TI  - Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol
AID  - 10.1101/2021.07.02.21259886
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.02.21259886
4099  - http://medrxiv.org/content/early/2021/07/06/2021.07.02.21259886.short
4100  - http://medrxiv.org/content/early/2021/07/06/2021.07.02.21259886.full
AB  - Introduction The government of India has rolled out COVID-19 vaccine program for individuals who are 18 years of age and above and priority is being given to the elderly, and individuals with morbidity. Oxford-AstraZeneca COVID-19 vaccine (COVISHIELD™) is most widely used in India. A large number of Indian people have been consuming various traditional medicines in the hope of better protection against COVID-19 infection. Several studies have reported immunological benefits of Ashwagandha and its potential as vaccine adjuvant. We plan to study co-administration of Ashwagandha with COVISHIELD™ vaccine on safety, immunogenicity and protection.Methods and analysis We designed a prospective, randomized, double blind, parallel group, placebo controlled, two arm, exploratory study on healthy volunteers receiving the COVISHIELD™ vaccine. In addition to the two dose schedule of COVISHIELD vaccine as per national guidelines, participants will be administered 8gm Ashwagandha or placebo tablets respectively per day. Primary outcome measure is immunogenicity as measured by SARS-CoV-2 spike (S1) and RBD-specific IgG antibody titres. Secondary outcome measures are safety, protective immune response and quality of life measures. Adverse event following immunization will be monitored at each time throughout the study. Participants will be tracked on a daily basis with a user friendly mobile phone application. Following power calculation 600 participants will be recruited per arm to demonstrate superiority by a margin of 7% with 80% power. Study duration is 28 weeks with interim analysis at the end of 12 weeks.Ethics and dissemination Ethical approval was obtained through the Central and institutional Ethics Committees. Participant recruitment is expected to commence by August 2021. Results will be presented in conferences and published in preprint followed by peer-reviewed medical journals.Registration details Clinical Trial Registry – India (CTRI) Registration Number: CTRI/2021/06/034496. Date of Registration June 30, 2021.Strengths and limitations of this studyNovel study to demonstrate effect of coadministration of immune adjuvant and COVID-19 vaccine on safety and immunogenicity.Randomised placebo controlled 28 weeks study with 80 percent power to demonstrate role of putative natural immunomodulator to augment the protection and reduce breakthrough infectionsState of art immune assays to measure specific antibodies to SARS-CoV-2 to demonstrate both persistent and late upsurge in immune responseDaily tracking of participants using a study specific designed mobile appAn interim analysis is planned to provide information on early immune response after first dose of vaccineParticipants may be reluctant to donate blood repeatedly for immune assays; compliance with the test drug may be a challenge; asymptomatic infections may be missed; the study is not measuring cellular immune response.Competing Interest StatementNone of the authors have any competing interest regarding this study. The authors BCS Rao, Babita Yadav, Narayanam Srikanth work at Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH (MoA), Government of India. Arvind Chopra is chief clinical coordinator designated by MoA. Bhushan Patwardhan is Chairman Interdisciplinary AYUSH R & D Task Force on COVID-19 established by MoA.Clinical TrialCTRI/2021/06/034496Funding StatementThis study will be funded by Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH (MoA), Government of India, New Delhi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A study of Ashwagandha co-administration with COVID-19 vaccine (COVISHIELD) on safety, immunogenicity and protection: A Randomized double blind placebo-controlled clinical trial, has been approved by the Central Ethics Committee (CEC) of Central Council for Research in Ayurvedic Sciences, New Delhi on 19th May 2021. Each collaborating institute shall obtain IEC approval before starting the trial.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe status of the study and the results (after final analysis) will be uploaded on CTRI Website URL - http://ctri.nic.in. http://www.ccras.nic.in/